Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. 2009

Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
Neuroimaging Section, Division of Psychological Medicine, PO67, Institute of Psychiatry, London SE58AF, England. p.fusar@libero.it

BACKGROUND Cannabis use can both increase and reduce anxiety in humans. The neurophysiological substrates of these effects are unknown. OBJECTIVE To investigate the effects of 2 main psychoactive constituents of Cannabis sativa (Delta9-tetrahydrocannabinol [Delta9-THC] and cannabidiol [CBD]) on regional brain function during emotional processing. METHODS Subjects were studied on 3 separate occasions using an event-related functional magnetic resonance imaging paradigm while viewing faces that implicitly elicited different levels of anxiety. Each scanning session was preceded by the ingestion of either 10 mg of Delta9-THC, 600 mg of CBD, or a placebo in a double-blind, randomized, placebo-controlled design. METHODS Fifteen healthy, English-native, right-handed men who had used cannabis 15 times or less in their life. METHODS Regional brain activation (blood oxygenation level-dependent response), electrodermal activity (skin conductance response [SCR]), and objective and subjective ratings of anxiety. RESULTS Delta9-Tetrahydrocannabinol increased anxiety, as well as levels of intoxication, sedation, and psychotic symptoms, whereas there was a trend for a reduction in anxiety following administration of CBD. The number of SCR fluctuations during the processing of intensely fearful faces increased following administration of Delta9-THC but decreased following administration of CBD. Cannabidiol attenuated the blood oxygenation level-dependent signal in the amygdala and the anterior and posterior cingulate cortex while subjects were processing intensely fearful faces, and its suppression of the amygdalar and anterior cingulate responses was correlated with the concurrent reduction in SCR fluctuations. Delta9-Tetrahydrocannabinol mainly modulated activation in frontal and parietal areas. CONCLUSIONS Delta9-Tetrahydrocannabinol and CBD had clearly distinct effects on the neural, electrodermal, and symptomatic response to fearful faces. The effects of CBD on activation in limbic and paralimbic regions may contribute to its ability to reduce autonomic arousal and subjective anxiety, whereas the anxiogenic effects of Delta9-THC may be related to effects in other brain regions.

UI MeSH Term Description Entries
D007091 Image Processing, Computer-Assisted A technique of inputting two-dimensional or three-dimensional images into a computer and then enhancing or analyzing the imagery into a form that is more useful to the human observer. Biomedical Image Processing,Computer-Assisted Image Processing,Digital Image Processing,Image Analysis, Computer-Assisted,Image Reconstruction,Medical Image Processing,Analysis, Computer-Assisted Image,Computer-Assisted Image Analysis,Computer Assisted Image Analysis,Computer Assisted Image Processing,Computer-Assisted Image Analyses,Image Analyses, Computer-Assisted,Image Analysis, Computer Assisted,Image Processing, Biomedical,Image Processing, Computer Assisted,Image Processing, Digital,Image Processing, Medical,Image Processings, Medical,Image Reconstructions,Medical Image Processings,Processing, Biomedical Image,Processing, Digital Image,Processing, Medical Image,Processings, Digital Image,Processings, Medical Image,Reconstruction, Image,Reconstructions, Image
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D010296 Parietal Lobe Upper central part of the cerebral hemisphere. It is located posterior to central sulcus, anterior to the OCCIPITAL LOBE, and superior to the TEMPORAL LOBES. Brodmann Area 39,Brodmann Area 40,Brodmann Area 5,Brodmann Area 7,Brodmann's Area 39,Brodmann's Area 40,Brodmann's Area 5,Brodmann's Area 7,Inferior Parietal Cortex,Secondary Sensorimotor Cortex,Superior Parietal Lobule,Angular Gyrus,Gyrus Angularis,Gyrus Supramarginalis,Intraparietal Sulcus,Marginal Sulcus,Parietal Cortex,Parietal Lobule,Parietal Region,Posterior Paracentral Lobule,Posterior Parietal Cortex,Praecuneus,Precuneus,Precuneus Cortex,Prelunate Gyrus,Supramarginal Gyrus,Area 39, Brodmann,Area 39, Brodmann's,Area 40, Brodmann,Area 40, Brodmann's,Area 5, Brodmann,Area 5, Brodmann's,Area 7, Brodmann,Area 7, Brodmann's,Brodmanns Area 39,Brodmanns Area 40,Brodmanns Area 5,Brodmanns Area 7,Cortex, Inferior Parietal,Cortex, Parietal,Cortex, Posterior Parietal,Cortex, Precuneus,Cortex, Secondary Sensorimotor,Cortices, Inferior Parietal,Gyrus, Angular,Gyrus, Prelunate,Gyrus, Supramarginal,Inferior Parietal Cortices,Lobe, Parietal,Lobule, Parietal,Lobule, Posterior Paracentral,Lobule, Superior Parietal,Paracentral Lobule, Posterior,Paracentral Lobules, Posterior,Parietal Cortex, Inferior,Parietal Cortex, Posterior,Parietal Cortices,Parietal Cortices, Inferior,Parietal Cortices, Posterior,Parietal Lobes,Parietal Lobule, Superior,Parietal Lobules,Parietal Lobules, Superior,Parietal Regions,Posterior Paracentral Lobules,Posterior Parietal Cortices,Precuneus Cortices,Region, Parietal,Secondary Sensorimotor Cortices,Sensorimotor Cortex, Secondary,Superior Parietal Lobules
D010364 Pattern Recognition, Visual Mental process to visually perceive a critical number of facts (the pattern), such as characters, shapes, displays, or designs. Recognition, Visual Pattern,Visual Pattern Recognition
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011605 Psychoses, Substance-Induced Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance. Psychoses, Drug,Psychoses, Toxic,Substance-Induced Psychoses,Toxic Psychoses,Drug Psychoses,Psychoses, Substance Induced,Substance Induced Psychoses
D011619 Psychotropic Drugs A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). Psychoactive Agent,Psychoactive Agents,Psychoactive Drug,Psychopharmaceutical,Psychopharmaceuticals,Psychotropic Drug,Psychoactive Drugs,Agent, Psychoactive,Agents, Psychoactive,Drug, Psychoactive,Drug, Psychotropic,Drugs, Psychoactive,Drugs, Psychotropic
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon

Related Publications

Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
March 1976, Clinical pharmacology and therapeutics,
Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
November 1974, Research communications in chemical pathology and pharmacology,
Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
November 1986, Neuropharmacology,
Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
June 1971, Science (New York, N.Y.),
Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
October 2012, Journal of psychopharmacology (Oxford, England),
Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
August 2016, Planta medica,
Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
April 2023, Experimental and clinical psychopharmacology,
Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
October 1973, Psychopharmacologia,
Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
August 2020, Medical cannabis and cannabinoids,
Paolo Fusar-Poli, and José A Crippa, and Sagnik Bhattacharyya, and Stefan J Borgwardt, and Paul Allen, and Rocio Martin-Santos, and Marc Seal, and Simon A Surguladze, and Colin O'Carrol, and Zerrin Atakan, and Antonio W Zuardi, and Philip K McGuire
September 1974, European journal of pharmacology,
Copied contents to your clipboard!